Sarcoidosis remains one of the most compelling unresolved clinical challenges. It is defined by non-caseating granulomatous inflammation and remarkable clinical heterogeneity (1, 2), but still lacks a unifying pathogenic framework (3). Despite substantial advances in immunology, purely immune-centered models have failed to fully explain why granulomatous inflammation emerges, persists, or resolves across patients and organs (3).
The Research Topic “Unlocking the Microbial Code: Potential Role in Sarcoidosis Pathogenesis and Treatment” was conceived to explore a converging line of evidence suggesting that sarcoidosis may arise from a dynamic and context-dependent interaction between the immune system and microbial ecosystems (4). The contributions gathered herein collectively point toward the microbiota—both intestinal and pulmonary—as an active immunological modulator capable of shaping macrophage behavior, T-cell polarization, and cytokine networks that underpin granuloma formation (5).
In this framework, the comprehensive review by Rizzi et al. critically integrates emerging metagenomic and immunological data, proposing that dysbiosis may represent a biologically meaningful component of disease susceptibility, phenotype, and progression rather than a secondary epiphenomenon.
From a translational perspective, the contribution by Ucciferri et al. further defines this paradigm by highlighting how antibiotic exposure can induce long-lasting perturbations of the host microbiota with potential downstream consequences for immune balance and inflammatory trajectories, raising timely and clinically relevant questions regarding antimicrobial stewardship in sarcoidosis.
At the tissue level, original research comparing lung granulomas in sarcoidosis and tuberculosis provides a crucial mechanistic bridge, revealing that sarcoid granulomas possess a distinct immune architecture and spatial organization despite histological similarities, underscoring that granulomatous inflammation is not a uniform endpoint but a finely tuned, context-specific immune structure. Complementary experimental evidence on pro-resolving mediators such as resolvin D2, although not disease-specific, reinforces the importance of resolution pathways in restoring immune homeostasis and suggests that failure to engage these mechanisms may contribute to persistent granulomatous inflammation.
Taken together, the studies in this Research Topic converge toward a more integrated and biologically nuanced model in which sarcoidosis might result, at least in a subset of patients, from the interplay between microbial signals, immune regulation, and tissue microenvironments (6). This conceptual evolution is closely aligned with recent advances emphasizing the need for a multidisciplinary approach to management and the integration of novel technologies in sarcoidosis care, where immunology, imaging, clinical phenotyping, and systems-based approaches converge to address several aspects of this complex disease (7).
In particular, emerging frameworks that incorporate advanced imaging modalities and refined therapeutic strategies—especially in high-risk organ involvement such as the heart, nervous system, and eye—underscore how deeper pathobiological insight can inform precision-oriented clinical decision-making (8–12). An overview of the key mechanisms, working hypotheses, and representative studies discussed by the articles included in this special issue is illustrated in Figure 1.
Figure 1
Provides a schematic overview of the pathogenetic hypotheses, and representative studies discussed in this special issue. Lung and gut dysbiosis along with the lung–gut axis might modulate immune responses, thus influencing the balance between granuloma formation and resolution. This integrated framework highlights how microbial alterations and immune modulation may inform targeted therapeutic strategies. (Figure created with Biorender. License number: IK29AAQCI8)..
By bringing microbiome science into the core of sarcoidosis research and embedding it within a broader multidisciplinary and technology-driven perspective, this topic supports a shift from empiric, broad immunosuppression to targeted strategies aimed at restoring immune–microbial homeostasis and redefining how this complex and heterogeneous disease is understood and managed.
Statements
Author contributions
CT: Writing – original draft, Writing – review & editing. NB: Writing – original draft, Writing – review & editing. PS: Writing – original draft, Writing – review & editing.
Funding
The author(s) declared that financial support was not received for this work and/or its publication.
Conflict of interest
The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Generative AI statement
The author(s) declared that generative AI was not used in the creation of this manuscript.
Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1
DrentMRussellAMSaketkooLASpagnoloPVeltkampMWellsAUet al. Breaking barriers: holistic assessment of ability to work in patients with sarcoidosis. Lancet Respir Med. (2024) 12:848–51. doi: 10.1016/S2213-2600(24)00297-2
2
TanaCSchiavoneC. The chameleon behavior of sarcoidosis. J Clin Med. (2021) 10:2780. doi: 10.3390/jcm10132780
3
TanaCDonatielloICaputoATanaMNaccarelliTMantiniCet al. Clinical features, histopathology and differential diagnosis of sarcoidosis. Cells. (2021) 11:59. doi: 10.3390/cells11010059
4
NouvenneATicinesiATanaCPratiBCataniaPMiragliaCet al. Digestive disorders and Intestinal microbiota. Acta BioMed. (2018) 89:47–51. doi: 10.23750/abm.v89i9-S.7912
5
HouKWuZXChenXYWangJQZhangDXiaoCet al. Microbiota in health and diseases. Signal Transduct Target Ther. (2022) 7:135. doi: 10.1038/s41392-022-00974-4
6
BeckerAVellaGGalataVRentzKBeisswengerCHerrCet al. The composition of the pulmonary microbiota in sarcoidosis - an observational study. Respir Res. (2019) 20:46. doi: 10.1186/s12931-019-1013-2
7
TanaCDrentMObiONCinettoFBernardinelloNMoffaLet al. Multidisciplinary strategies and new technologies in the management of sarcoidosis. Eur J Intern Med. (2025) 1:106576. doi: 10.1016/j.ejim.2025.106576
8
TanaCKouranosVBernardinelloNMantiniCScarpaRCinettoFet al. Redefining cardiac sarcoidosis with advanced imaging and therapeutic strategies. Am J Cardiovasc Drugs. (2025). doi: 10.1007/s40256-025-00783-4
9
Israël-BietDBernardinelloNPastréJTanaCSpagnoloP. High-risk sarcoidosis: A focus on pulmonary, cardiac, hepatic and renal advanced diseases, as well as on calcium metabolism abnormalities. Diagnostics (Basel). (2024) 14:395. doi: 10.3390/diagnostics14040395
10
TanaCBernardinelloNRaffaelliBGarcia-AzorinDWaliszewska-ProsółMTanaMet al. Neuropsychiatric manifestations of sarcoidosis. Ann Med. (2025) 57:2445191. doi: 10.1080/07853890.2024.2445191
11
De CremNWuytsWA. Emerging diagnostic techniques in sarcoidosis: a path forward. Curr Opin Immunol. (2026) 99:102716. doi: 10.1016/j.coi.2025.102716
12
TanaCDrentMNunesHKouranosVCinettoFJessurunNTet al. Comorbidities of sarcoidosis. Ann Med. (2022) 54:1014–35. doi: 10.1080/07853890.2022.2063375
Summary
Keywords
granulomatous inflammation, microbiota–immune interactions, multidisciplinary management, precision medicine, sarcoidosis
Citation
Tana C, Bernardinello N and Spagnolo P (2026) Editorial: Unlocking the microbial code: potential role in sarcoidosis pathogenesis and treatment. Front. Immunol. 17:1796347. doi: 10.3389/fimmu.2026.1796347
Received
26 January 2026
Revised
10 February 2026
Accepted
10 February 2026
Published
19 February 2026
Volume
17 - 2026
Edited and reviewed by
Ian Marriott, University of North Carolina at Charlotte, United States
Updates
Copyright
© 2026 Tana, Bernardinello and Spagnolo.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Claudio Tana, claudio.tana@asl.taranto.it
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.